SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 21, 2021 / Pascal Biosciences, Inc. ('Pascal' or the 'Company') (TSXV:PAS)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascal's development program for treatment of glioblastoma with PAS-403. The title of his presentation is 'Discovery & Development of a Cannabinoid-Derived Therapeutic for Glioblastoma'.

The Cannabinoid Derived Pharmaceuticals Industry Review Summit is the first European conference aimed to address challenges in the clinical development and commercialization of cannabinoids and drugs derived from cannabinoids. Based in London, this virtual conference is the premier format for presentation of ground-breaking discoveries in cannabinoid drug development. This meeting is hosting pharmaceutical experts developing therapeutics derived from cannabis. In addition to describing progress for Pascal's program in glioblastoma, Dr. Gray will also discuss plans for developing PAS-393 for treatment of cancer in combination with checkpoint inhibitors. This collaborative effort with SōRSE Technology aims to characterize the safety, pharmacology, and pharmacokinetics of PAS-393 in a Phase 1a clinical trial.

'I am very pleased for the invitation to present Pascal's work at this impressive conference,' commented Dr. Gray. 'This validates the importance of our efforts, and we will be featured with other companies making significant advancements in developing cannabis-based medicines.' The session featuring Pascal's presentation is titled 'Linking Cannabinoids to their Therapeutic Potential'.

ABOUT PASCAL BIOSCIENCES INC.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy which is being developed collaboratively with SoRSE Technology.

To learn more, visit: https://www.pascalbiosciences.com/.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, President & CEO

Company Contact:
Dr. Patrick Gray

Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443

Forward-Looking Statements

DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words 'believe', 'may', 'plan', 'will', 'estimate', 'continue', 'anticipate', 'intend', 'expect' and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

'Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release'

SOURCE: Pascal Biosciences Inc.